XML 31 R16.htm IDEA: XBRL DOCUMENT
v3.22.4

Intangible assets, net and Goodwill | 12 Months Ended
--- | ---
Dec. 31, 2022
Intangible assets, net and Goodwill |
Intangible assets, net and Goodwill | ​ 10. Intangible assets, net and Goodwill ​ The following table presents the Company’s acquired licenses and acquired IPR&D as of December 31: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | December 31, |  | December 31,
​ | ​ | 2022 | ​ | 2021
​ | ​ | (in thousands)
Acquired licenses | ​ | $ | 2,346 | ​ | $ | 4,755
Less accumulated amortization | ​ | ​ | (900) | ​ | ​ | (2,827)
Acquired licenses, net | ​ | $ | 1,446 | ​ | $ | 1,928
Acquired IPR&D Intangible Asset | ​ |  | 57,332 | ​ |  | 60,758
Intangibles, net | ​ | $ | 58,778 | ​ | $ | 62,686
​
| a. | Acquired licenses
​ All acquired licenses are owned by uniQure biopharma B.V, a subsidiary of the Company. The remaining weighted average life is 11.5 years as of December 31, 2022. (December 31 , 2021 10.8 years.) ​ ​ As of December 31, 2022, the estimated future amortization expense for each of the five succeeding years and the period thereafter is as follows: ​
​ | ​ | ​ | ​
Years |  | Amount
​ | ​ | (in thousands)
2023 | ​ | $ | 126
2024 | ​ |  | 126
2025 | ​ |  | 126
2026 | ​ |  | 126
2027 | ​ |  | 126
Thereafter | ​ |  | 816
Total | ​ | $ | 1,446
​ The amortization expense related to licenses for the year ended December 31, 2022 was $0.4 million (December 31, 2021: $1.2 million; December 31, 2020: $4.6 million). In 2020, the Company disposed of a number of licenses determined to have no alternative future use. The impairment expense related to licenses for the year ended December 31, 2022 was $0.0 million (December 31, 2021: $0.0 million; December 31, 2020 $0.3 million). ​
| b. | Acquired in-process research and development
​ As part of its acquisition of Corlieve as of July 30, 2021, the Company identified certain intangible assets related to an IPR&D Intangible Asset. Refer to Note 3 “Corlieve transaction”. ​
| c. | Goodwill
​ As part of its acquisition of Corlieve as of July 30, 2021, the Company recorded goodwill. Refer to Note 3 “Corlieve transaction”.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI https://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration